Lars Hedbys
Dr. Lars Hedbys joined Ventac Partners in 2006. He contributes with over 30 years international leadership experience from the life science industry. He has a track record of leading listed companies, large operational organizations, organizations in change as well as founding and growing life science companies to an IPO. He has led companies in various fields of the industry including pharmaceutical development, ATMP development, medical device development and marketing, contract research organisations as well as leading private medical clinics. Lars Hedbys is currently serving as chairman or board member on a number of listed and private companies in the life science industry.
Important positions in Lars Hedbys’ curriculum include: CEO of Idogen AB (listed on Nasdaq First North, Stockholm), Chairman of the Lund Life Science Incubator, CEO of Glycorex Transplantation AB (listed on the NGM stock exchange, Stockholm), CEO of AB Mando, General Manager of Synarc A/S, Vice President and Site General Manager of AstraZeneca R&D Lund and Vice President, Global Clinical Operations & Project Management of AstraZeneca R&D. He is also co-founder of Idogen AB, Regenesance BV, IAmPatient AB and Casigen Pharma Ltd.
Lars Hedbys holds a M.Sc. in chemical engineering from Chalmers University of Technology and a Ph.D. in Applied Biochemistry from the University of Lund.